CHARLES RIVER LABORATORIES INTL. overview

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River’s Endosafe ® bacterial endotoxin testing (BET) cartridge technology an avenue to responsibly recycle single-use plastic cartridges used specifically for routine water testing. The cartridge recycling program...

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45 th Annual Growth Stock Conference on Tuesday, June 3 rd , at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4 th , at 10:30 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will...

Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future. The organizations began working together in 2005 to expedite therapeutic development for Huntington’s disease (HD) , a genetic neurological disorder that causes the progressive dysfunction of nerve cells in the brain. The extension in 2025, marking the 20-year anniversary of the collaboration, will allow more...

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Bank of America 2025 Health Care Conference on Wednesday, May 14 th , at 8:40 a.m. PT (11:40 a.m. ET). Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com . A...

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the GAAP operating margin decreased to 7.6%...

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company’s business focused on enhancing long-term value for shareholders. Charles River’s Board of Directors has agreed to appoint four new directors, Steven...

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the initial cohort of its Charles River Incubator Program (CIP). Launched in December 2024 , the program offers early-stage biotechnology pioneers access to extensive scientific and commercial expertise and a wide ecosystem of discovery, development, and manufacturing capabilities to expedite the development of technologies and life-changing therapies for patients in need. The first cohort includes six advanced therapy...

Charles River Laboratories International, Inc. (NYSE: CRL), ahead of the American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive portfolio of products and services supporting the discovery and development of novel oncology drugs. Based solely on projected population growth, the number of cancer cases is predicted to increase to 35 million by 2050, and approximately 1 in 5 individuals will develop cancer in their lifetime....